ARTICLE | Deals
AbbVie seeks further extension to immunology franchise via $10.9B Apogee deal
Takeout adds long-acting atopic dermatitis therapy, headed into Phase III, that could compete with Dupixent and Ebglyss
June 22, 2026 11:44 PM UTC
AbbVie’s $10.9 billion purchase of Apogee will give the pharma long-acting dermatological and respiratory programs that could further extend its immunology franchise beyond the newer blockbusters that replaced Humira as its top sellers.
Assuming its completion, the deal will give AbbVie Inc. (NYSE:ABBV) late-stage candidate zumilokibart, a long-acting IL-13 inhibitor that has generated promising data in atopic dermatitis. AbbVie characterized it as the primary driver of the agreement in a presentation early Monday...